Key Data

 

 

2015

 

2016

 

Change

 

 

€ million

 

€ million

 

%

2015 figures restated; figures for 2012–2014 as last reported

1

For definitions of the indicators see Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Employees calculated as full-time equivalents (FTEs)

3

Number of incidents per 200,000 working hours in which chemicals leak from their primary container, such as pipelines, pumps, tanks or drums

4

Quotient of total energy consumption and manufactured sales volume; Life Sciences only

5

Direct emissions from power plants, waste incinerators and production plants and indirect emissions from external supplies of electricity, steam and refrigeration (according to the market-based method); portfolio-adjusted in accordance with the GHG Protocol

6

Life Sciences without Currenta

Bayer Group

 

 

 

 

 

 

Sales

 

46,085

 

46,769

 

+1.5

EBITDA1

 

9,573

 

10,785

 

+12.7

EBITDA before special items1

 

10,256

 

11,302

 

+10.2

EBITDA margin before special items1

 

22.3%

 

24.2%

 

 

EBIT1

 

6,241

 

7,042

 

+12.8

EBIT before special items1

 

7,060

 

8,130

 

+15.2

Income before income taxes

 

5,236

 

5,887

 

+12.4

Net income (from continuing and discontinued operations)

 

4,110

 

4,531

 

+10.2

Earnings per share (from continuing and discontinued operations) (€)1

 

4.97

 

5.44

 

+9.5

Core earnings per share (from continuing operations) (€)1

 

6.82

 

7.32

 

+7.3

Net cash provided by operating activities (from continuing and discontinued operations)

 

6,890

 

9,089

 

+31.9

Net financial debt

 

17,449

 

11,778

 

−32.5

Capital expenditures

 

2,511

 

2,578

 

+2.7

 

 

 

 

 

 

 

Bayer AG

 

€ million

 

€ million

 

%

Total dividend payment

 

2,067

 

2,233

 

+8.0

Dividend per share (€)

 

2.50

 

2.70

 

+8.0

 

 

 

 

 

 

 

Innovation

 

€ million

 

€ million

 

%

Research and development expenses

 

4,274

 

4,666

 

+9.2

Ratio of R&D expenses to sales – Pharmaceuticals (%)

 

16.0

 

17.0

 

 

Ratio of R&D expenses to sales – Crop Science (%)

 

10.7

 

11.7

 

 

Employees in research and development

 

14,753

 

15,229

 

+3.8

 

 

 

 

 

 

 

Employees

 

 

 

 

 

 

Number of employees2 (Dec. 31)

 

116,600

 

115,200

 

−1.2

Personnel expenses (including pension expenses) (€ million)

 

11,176

 

11,357

 

+1.6

Proportion of women in senior management (%)

 

28

 

29

 

 

Proportion of employees with health insurance (%)

 

96

 

98

 

 

Fluctuation (voluntary / total) (%)

 

5.0 / 13.9

 

4.6 / 12.3

 

 

Hours of vocational and ongoing training per employee

 

20.0

 

22.1

 

+10.5

 

 

 

 

 

 

 

Safety & Environmental Protection

 

 

 

 

 

 

Recordable Incident Rate for Bayer employees (RIR)

 

0.42

 

0.39

 

−7.1

Loss of Primary Containment Incident Rate (LoPC-IR)3

 

0.22

 

0.32

 

+45.5

Total energy consumption (terajoules)

 

83,182

 

84,494

 

+1.6

Energy efficiency (MWh/t)4

 

6.34

 

6.77

 

+6.8

Total greenhouse gas emissions (CO2 equivalents in million t)5

 

9.71

 

9.87

 

+1.6

Specific greenhouse gas emissions (CO2 equivalents in t / manufactured sales volume in t), according to the market-based method6

 

1.69

 

1.54

 

−8.9

Hazardous waste generated (thousand t)

 

541

 

547

 

+1.1

Water use (million m3)

 

346

 

330

 

−4.6